National Institute of Diabetes and Digestive and Kidney Diseases

So the distinction is incredibly important.

So they did a review in 2026, I believe, that describes the concept of moving beyond simple clinical closure towards functional closure, okay? Which is like restoration of sufficient epidermal barrier competence to limit the trans-epidermal water loss and the skin being able to tolerate mechanical trauma better, okay? So that brings us to this study that was done in 2025, right? By the NIDDK Diabetic Foot Consortium.

I know I did not pronounce that right.

Forgive me.

The first one is on type 1 diabetes and cardiorenal outcomes, informing a practice-changing trial.

And this has been organized by the Diabetes Melitus Interagency Coordinating Committee and with support from the National Institute of Diabetes and Digestive and Kidney Diseases, together with the National Heart, Lung, and Blood Institute, and will occur on September 18th.

The second meeting is on accelerating the translation of cell therapy for type 1 diabetes, and has been organized by the National Institute of Diabetes and Digestive and Kidney Diseases, together with Breakthrough T1D, and will be occurring on September 22nd and 23rd.

Both meetings are bringing together broad complimentary expertise to address unmet needs for reducing morbidity and mortality from and ultimately curing type one diabetes.

And you can register for each online.

The ADA, the American Diabetes Association, is another good resource for both healthcare professionals and the public.

And for people who want more accessible and readable information, the NIH and NIDDK have useful patient-oriented material.

And I think the bottom line here would be look for sources that cite the actual studies, disclose their conflicts of interest, and are willing to discuss both what the drugs can do and what they can't do, as opposed to either.

Yeah, well, this has been a really fascinating walk through this.

So I went to Genentech and I said, "Genentech, well, look, now I have $3 million.

What are you going to do?" And they said, "Now that you have that, we give you..." Then they talk and said, "Well, we give you the other 50%," and then is missing 2 point- 25% of this, and you go and ask the NIDDK for that 25%.

So then I had $7.5 million in my pocket.

In I end- I went to the NIDDK, the National Institute of Animal Health for, uh, kidney disease, all right? To Dr.

Star and his groups, all right? Asking for the first randomized control study in membranous nephropathy done in 30 years in this country, where we had done the pharmacokinetics, the pharmacodynamics, the timelines, the dosing, and we had a biomarker without costing the federal government a single dollar, right? And we asked them to give us $2.5 million.

In other words, $500,000 a year for five years.

Put that in perspective.

The study was evaluated by the NIDDK.

Than it was so much...

Uh, he's one of the leaders at the NIDDK.

I hope he's listening to this.

And is he, is he a kidney stone guy, or is he just a k- a kidney guy? He's a, he's a nephrologist.

It was conducted between 2017 and 2024 in the United States.

There were six medical centers that were involved.

The protocol was improved by the NIDDK.

There was, um, pretty basic inclusion criteria.

beset by diarrhea.

The National Institute of Diabetes and Digestive and Kidney Diseases says that diverticulosis often comes from a lifestyle in which the patient is obese and eats a low fiber, high red meat content diet.

Oh, Well, Mr.

Big Macs, two hamburgers.